The iPhone maker's shares [rallied for a second day]( ...

A late-stage study tested three doses of Eli Lilly’s oral GLP-1 drug, Orforglipron, in more than 3,100 adults, with the ...

NEW YORK (AP) — Stocks are rising on Wall Street Thursday, even as President Donald Trump’s latest tariffs kicked into effect ...

In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...

Drugmaker Eli Lilly said Thursday that things are looking good for their latest weight loss drug that would be available as a ...

Emmy Nominees In Comedy Casting Sound Off On Self Tapes, Future Of Their Jobs & Whether Trump's Assault On DEI Should Worry Hollywood ...

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...

In a clinical trial, the company's weight loss pill resulted in a nearly 12% weight loss at 72 weeks for participants who took the highest dose of the medication. On average, participants lost 7.8% to ...

Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill ...

Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.

Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may ...

Pirtobrutinib had a nominally superior overall response rate compared to ibrutinib in certain patients with chronic ...